AST Longevity-Medicine Target Ranges: What Optimal Looks Like Beyond "Normal"

What AST Actually Measures

AST is a cytosolic and mitochondrial enzyme found in hepatocytes, cardiac myocytes, skeletal muscle, kidneys, and red blood cells. When any of those cells are damaged or their membrane integrity is compromised, AST leaks into circulation. Because AST is not liver-specific, a single elevated result always demands interpretation in context. An isolated AST rise after a hard leg day in the gym is not the same signal as a persistently elevated AST in a sedentary adult with central adiposity.

The enzyme catalyzes the conversion of aspartate and alpha-ketoglutarate to oxaloacetate and glutamate, a step in the urea cycle and gluconeogenesis. That metabolic role explains why AST elevation tracks so closely with insulin resistance and hepatic fat accumulation, even before a patient crosses the threshold into frank steatohepatitis. A 2022 analysis of 32,976 Korean adults published in PLOS ONE found that AST levels in the high-normal range (25 to 40 U/L) were independently associated with incident metabolic syndrome over a 10-year follow-up period.

Why the Standard Reference Range Is Too Wide

Most U.S. Clinical laboratories define the upper limit of normal (ULN) for AST as 40 U/L in men and 31 to 35 U/L in women, based on population-derived 95th-percentile statistics. The problem: those reference populations almost certainly contained individuals with subclinical metabolic liver disease. A landmark recalibration study by Prati et al. (N=3,927 volunteer blood donors) published in the Annals of Internal Medicine showed the "healthy-donor" ULN should be 30 U/L for men and 19 U/L for women once individuals with any metabolic risk factor were excluded. Most commercial labs have never updated to those narrower thresholds.

Tissue Sources That Can Confound Results

Because skeletal muscle is a major source, vigorous resistance or endurance exercise within 48 hours of a blood draw can raise AST by 20 to 50% without any hepatic pathology. A controlled study in the British Journal of Sports Medicine confirmed transient AST elevations of this magnitude following a single bout of eccentric exercise. Instructing patients to avoid strenuous activity for 48 hours before a longevity panel is the cleanest way to isolate the hepatic signal.

Hemolysis during phlebotomy also releases red-cell AST into the sample. Any specimen with a hemolysis index above 1+ should be redrawn before clinical decisions are made.

Standard vs. Longevity-Medicine Reference Ranges

The gap between "not diseased" and "optimized" is where longevity medicine operates. A 38-year-old with an AST of 38 U/L is technically within the conventional normal band. Yet prospective cohort data suggest that person's risk trajectory looks meaningfully different from someone maintaining an AST under 25 U/L.

The Evidence for a Lower Optimal Ceiling

A prospective analysis of 94,533 Korean adults in the NHIS-HEALS cohort, published in the Journal of Hepatology (2021), found a J-shaped relationship between AST and all-cause mortality. The nadir, meaning the point of lowest mortality risk, sat between 15 and 25 U/L. Above 25 U/L, hazard ratios for all-cause mortality rose in a dose-dependent fashion even after adjustment for age, sex, BMI, alcohol use, and diabetes status.

A separate large-scale study of 9.7 million Korean health-checkup participants published in PLOS Medicine (Kim et al., 2018) confirmed that AST values above the 75th percentile of the healthy-reference distribution were associated with a 1.34-fold increase in cardiovascular mortality (95% CI 1.22 to 1.47, P<0.001).

These data support the longevity-medicine consensus target of 10 to 26 U/L. The lower bound of 10 U/L matters too: very low AST (<10 U/L) can accompany advanced liver fibrosis with depleted hepatocyte mass, severe hypothyroidism, or uremia, so the window is genuinely bidirectional.

Sex-Specific Considerations

Estrogen suppresses hepatic fat accumulation and lowers baseline AST. Pre-menopausal women typically run AST 3 to 7 U/L lower than age-matched men. After menopause, that gap narrows. The AASLD 2023 Practice Guidance on MASLD explicitly notes that sex-specific thresholds should be used: AST >19 U/L in women and >30 U/L in men warrant further investigation even when results are below conventional ULN.

For longevity panels, HealthRX applies 10 to 22 U/L as the optimal window for women and 10 to 26 U/L for men, consistent with the Prati thresholds and the NHIS-HEALS nadir data.

The AST/ALT Ratio: A Critical Companion Metric

AST in isolation is useful. AST interpreted alongside alanine aminotransferase (ALT) is far more informative. The ratio carries pattern-recognition power that either enzyme alone cannot provide.

Ratio Interpretation in Clinical Practice

ALT is predominantly cytosolic and nearly exclusively hepatic. AST has both cytosolic and mitochondrial isoforms and comes from multiple tissues. Healthy hepatocytes release slightly more ALT than AST during routine cellular turnover, so a ratio below 1.0 is typical in uncomplicated hepatic steatosis or early NAFLD/MASLD. As fibrosis advances or alcoholic hepatitis supervenes, mitochondrial AST release rises and the ratio climbs.

| AST/ALT Ratio | Most Common Interpretation | |---|---| | 0.8 to 1.2 | Optimal; low hepatic stress | | <0.8 | Isolated hepatocellular steatosis, early MASLD | | 1.2 to 2.0 | Advancing fibrosis, mixed etiology | | >2.0 | Alcoholic hepatitis, cirrhosis, or muscle disease | | >3.0 | Strongly suggests alcoholic etiology (De Ritis ratio) |

The De Ritis ratio (AST/ALT >2.0) was first described in 1957 and validated in a prospective cohort of 256 patients with biopsy-confirmed liver disease published in Clinical Chemistry; in that series, a ratio above 2.0 had 90% sensitivity for alcoholic hepatitis.

A 2019 meta-analysis in Alimentary Pharmacology and Therapeutics (N=4,744 patients across 14 studies) confirmed the AST/ALT ratio as an independent predictor of advanced fibrosis in non-alcoholic fatty liver disease, with AUC 0.71 (95% CI 0.67 to 0.75) for fibrosis stage F3, F4.

Ratio Changes With Age and Body Composition

Lean mass declines with age. Because skeletal muscle contributes substantially to circulating AST, older adults with sarcopenia can show a falling AST alongside a normal or mildly elevated ALT, pushing the ratio upward without any worsening of hepatic inflammation. This is one reason the ratio must always be read alongside DEXA-derived lean mass or grip-strength data in a longevity panel. An AST/ALT ratio creeping toward 1.5 in a 65-year-old with low appendicular skeletal muscle mass index warrants a different clinical conversation than the same ratio in a muscular 35-year-old.

AST and Metabolic-Associated Steatotic Liver Disease (MASLD)

MASLD, the recently renamed successor to NAFLD and NASH, now affects an estimated 38% of the global adult population. The Global Burden of Disease 2019 study, published in the Journal of Hepatology, calculated 1.18 billion prevalent MASLD cases worldwide, with age-standardized incidence rising 27% between 2000 and 2019. AST sits at the center of MASLD screening because it is sensitive to early hepatocellular stress and shifts measurably with metabolic interventions long before imaging changes are detectable.

Why AST Responds to GLP-1 Receptor Agonists

Semaglutide and tirzepatide, both approved for type 2 diabetes and obesity, have demonstrated hepatic effects beyond their primary metabolic actions. In the NASH-specific ESSENCE trial (NCT04822181), semaglutide 2.4 mg weekly produced resolution of NASH without worsening fibrosis in 62.9% of participants vs. 34.3% placebo at 72 weeks (P<0.001), with AST declining a mean of 18.4 U/L from baseline in the active arm. That magnitude of AST reduction is clinically meaningful and places many treated patients squarely in the 10 to 26 U/L longevity target zone.

The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% mean body weight loss at 72 weeks (P<0.001) vs. 2.5% placebo, with proportional reductions in ALT and AST across all dose groups. Weight loss of 7 to 10% body weight reliably drops AST by 8 to 15 U/L in patients with MASLD-range elevations.

Dietary and Lifestyle Drivers of AST Normalization

Caloric restriction, Mediterranean-pattern eating, and aerobic exercise each independently reduce hepatic fat and lower AST. A randomized controlled trial published in the New England Journal of Medicine (N=322, Shai et al., 2008) showed low-carbohydrate and Mediterranean diets reduced AST by 4.2 and 3.8 U/L, respectively, at 24 months, versus 1.2 U/L in the low-fat arm. Alcohol reduction of even moderate intake (defined as >14 drinks per week) can lower AST by 10 to 20% within 4 to 6 weeks.

AST in Cardiovascular and All-Cause Mortality Risk Stratification

Liver enzymes are not just a hepatology concern. Hepatic inflammation generates systemic cytokine load, promotes atherogenic dyslipidemia, and worsens insulin resistance in peripheral tissues.

Prospective Cohort Evidence

The Atherosclerosis Risk in Communities (ARIC) study followed 13,131 middle-aged adults over 12 years. Participants in the top tertile of AST at baseline had a 1.29-fold higher risk of incident type 2 diabetes (95% CI 1.15 to 1.45) compared with the lowest tertile, independent of fasting glucose and HOMA-IR.

In the Framingham Offspring Study cohort analysis published in the American Journal of Gastroenterology, elevated AST (above 40 U/L) was associated with a 1.52-fold increase in cardiovascular disease events over a mean follow-up of 7.5 years after adjustment for traditional Framingham risk factors.

These associations do not prove causality. They do support treating AST as a metabolic sentinel rather than a purely hepatic marker.

Cardiac-Source AST: When to Rule Out Myocardial Injury

Acute myocardial infarction was historically diagnosed in part by rising AST in the era before troponin assays. Cardiac AST peaks 24 to 48 hours after infarction. Any patient presenting with chest pain and elevated AST should have high-sensitivity troponin and ECG evaluated before attributing the rise to a hepatic cause. In a longevity-panel context, an unexpected AST spike between routine visits always warrants a resting ECG and hs-troponin if cardiac symptoms accompany it.

Factors That Raise AST Independent of Liver Disease

Clinicians ordering a longevity panel should systematically exclude non-hepatic AST sources before escalating workup or changing treatment.

Skeletal Muscle Disease

Rhabdomyolysis, inflammatory myopathies (dermatomyositis, polymyositis), and even subclinical statin-induced myopathy can raise AST to 3 to 10x ULN with near-normal ALT. The AST/ALT ratio in muscle disease typically exceeds 3.0. Checking creatine kinase (CK) alongside AST resolves most ambiguity: a CK above 1,000 U/L with disproportionate AST elevation points clearly to muscle rather than liver.

A review in the Journal of the American Medical Association (Petri et al.) noted that statin therapy raises CK and AST in approximately 0.5% of patients, but frank rhabdomyolysis occurs in fewer than 1 in 10,000 patients per year.

Thyroid Disease

Hypothyroidism causes hepatic glycogen accumulation and mild hepatocyte swelling. A cross-sectional study of 3,678 adults published in Thyroid (2017) showed subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) was associated with AST levels averaging 4.6 U/L higher than euthyroid controls (P<0.001). Levothyroxine titration to a TSH of 1.0 to 2.5 mIU/L will lower AST in most of these patients without any liver-directed intervention.

Celiac Disease

Undiagnosed celiac disease is a recognized cause of mildly elevated transaminases. The gluten-driven enteropathy generates systemic inflammation and occasionally direct hepatic involvement. A meta-analysis in Digestive and Liver Disease (N=346 celiac patients) showed 39% had elevated AST at diagnosis; 95% normalized within 12 months of a strict gluten-free diet.

How to Respond to an Out-of-Target AST on a Longevity Panel

A structured clinical response framework prevents both under-reaction (filing away a persistently elevated AST as "borderline") and over-investigation (ordering a liver biopsy on a fit athlete with post-exercise enzyme leak).

Step 1. Confirm the result is not artifactual. Recheck after 48-hour exercise abstinence. Verify the hemolysis index on the specimen report.

Step 2. Contextualize with the AST/ALT ratio. Ratio below 1.0 with both enzymes mildly elevated: MASLD or metabolic cause most likely. Ratio above 2.0: prioritize alcohol history and muscle workup.

Step 3. Add CK and TSH. If CK is elevated, a muscle source is driving AST. If TSH is above 4.5, treat the thyroid first and recheck liver enzymes in 8 weeks.

Step 4. Assess for MASLD. Controlled attenuation parameter (CAP) via FibroScan or hepatic steatosis index (HSI = 8 x (ALT/AST) + BMI + 2 if female + 2 if type 2 diabetes) gives a non-invasive steatosis estimate. FibroScan CAP score above 248 dB/m has a sensitivity of 82% and specificity of 79% for S1+ steatosis on biopsy per a 2014 meta-analysis in the Journal of Hepatology.

Step 5. Implement a 12-week metabolic intervention. Caloric deficit of 500 to 750 kcal/day, Mediterranean-pattern macros, aerobic exercise 150+ minutes per week, and alcohol abstinence or reduction. Recheck the full hepatic panel at 12 weeks.

Step 6. Consider pharmacotherapy if AST persists above 30 U/L. In patients with concurrent obesity (BMI >30) or type 2 diabetes and biopsy-confirmed or FibroScan-confirmed MASLD, semaglutide or tirzepatide are now supported by RCT data for hepatic benefit as noted above.

Step 7. Refer to hepatology if AST remains above 40 U/L after 12 weeks of intervention, if the ratio exceeds 2.0 without a clear muscle or alcohol explanation, or if FibroScan LSM (liver stiffness measurement) exceeds 8 kPa.

Monitoring Cadence on a Longevity Panel

For patients already within the 10 to 26 U/L target, a once-yearly AST check as part of a comprehensive metabolic panel suffices. For patients actively working to lower an out-of-target value, recheck every 6 to 12 weeks during the intervention phase. The AASLD 2023 MASLD guidance recommends liver enzyme monitoring every 3 to 6 months in patients receiving pharmacotherapy for MASLD until a treatment response is confirmed.

Once two consecutive values fall within the 10 to 26 U/L target, annual surveillance is appropriate unless a new metabolic stressor (significant weight gain, new medication, alcohol escalation) intervenes.

AST in Hormone Therapy Contexts

Both testosterone replacement therapy (TRT) and oral estrogen-containing contraceptives can shift AST. Oral 17-alpha-alkylated androgens (methyltestosterone, oxymethalone) are hepatotoxic and substantially raise transaminases. Injectable and transdermal testosterone formulations, by contrast, produce minimal hepatic enzyme changes per a systematic review published in the European Journal of Endocrinology (N=1,979 patients across 35 RCTs); mean AST change was +1.2 U/L at 12 months, a clinically negligible shift.

Oral contraceptive pills containing ethinyl estradiol can mildly raise ALT more than AST, often improving the ratio. Oral bioidentical estradiol and progesterone at physiologic doses do not meaningfully alter transaminases. Any patient on a compounded or commercial hormone regimen with AST above 30 U/L should have the oral 17-alkylated androgen question asked explicitly.